[PART I. FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) This section presents the company's financial statements, management's discussion and analysis, market risk disclosures, and controls and procedures [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) The unaudited condensed financial statements for the period ended June 30, 2023, show a decrease in total assets to $341.5 million from $364.0 million at year-end 2022, primarily due to a reduction in cash and investments used to fund operations [Condensed Balance Sheets](index=3&type=section&id=Condensed%20Balance%20Sheets) As of June 30, 2023, total assets decreased to $341.5 million from $364.0 million, mainly due to reduced cash and investments, while total stockholders' equity fell to $299.5 million | Balance Sheet Items (in thousands) | June 30, 2023 (unaudited) | December 31, 2022 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $33,703 | $51,426 | | Short-term investments | $269,586 | $275,590 | | Total current assets | $309,302 | $332,439 | | Total assets | $341,500 | $364,010 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $17,904 | $16,507 | | Total liabilities | $42,031 | $43,270 | | Accumulated deficit | ($145,437) | ($110,470) | | Total stockholders' equity | $299,469 | $320,740 | [Unaudited Condensed Statements of Operations and Comprehensive Loss](index=4&type=section&id=Unaudited%20Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For the three and six months ended June 30, 2023, the company reported net losses of $17.5 million and $35.0 million, respectively, driven by increased research and development and general administrative expenses | Statement of Operations (in thousands) | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | :--- | :--- | | Collaboration revenue | $1,057 | $2,365 | $3,105 | $3,954 | | Research and development | $14,924 | $14,086 | $30,789 | $24,270 | | General and administrative | $6,881 | $5,540 | $13,345 | $10,487 | | Loss from operations | ($20,748) | ($17,261) | ($41,029) | ($30,803) | | Interest income | $3,240 | $373 | $6,062 | $505 | | **Net loss** | **($17,508)** | **($16,888)** | **($34,967)** | **($30,298)** | | Net loss per share, basic and diluted | ($0.42) | ($0.41) | ($0.84) | ($0.73) | [Unaudited Condensed Statements of Stockholders' Equity](index=5&type=section&id=Unaudited%20Condensed%20Statements%20of%20Stockholders%27%20Equity) Stockholders' equity decreased from $320.7 million at December 31, 2022, to $299.5 million at June 30, 2023, primarily due to the $35.0 million net loss for the period | Change in Stockholders' Equity (in thousands) | Six Months Ended June 30, 2023 | | :--- | :--- | | Balance at December 31, 2022 | $320,740 | | Stock-based compensation | $10,974 | | Exercise of common stock options & ESPP | $2,108 | | Net loss | ($34,967) | | Other changes | $414 | | **Balance at June 30, 2023** | **$299,469** | [Unaudited Condensed Statements of Cash Flows](index=7&type=section&id=Unaudited%20Condensed%20Statements%20of%20Cash%20Flows) Net cash used in operating activities significantly increased to $29.0 million for the six months ended June 30, 2023, primarily due to a higher net loss, resulting in a $17.7 million overall decrease in cash | Cash Flow Summary (in thousands) | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | | :--- | :--- | :--- | | Net cash used in operating activities | ($28,965) | ($17,595) | | Net cash provided by investing activities | $9,134 | $40,107 | | Net cash provided by financing activities | $2,108 | $309 | | **Net (decrease) increase in cash** | **($17,723)** | **$22,821** | [Notes to Unaudited Condensed Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Condensed%20Financial%20Statements) Key notes detail the company's liquidity, collaboration agreement with Merck, commitments, and equity structure, including a subsequent $56.5 million capital raise - The company is a clinical-stage biopharmaceutical firm that has incurred net losses since inception, with an accumulated deficit of **$145.4 million** as of June 30, 2023, but management believes it has sufficient capital for at least the next 12 months[22](index=22&type=chunk)[23](index=23&type=chunk) - The company recognized **$3.1 million** in revenue from its collaboration with Merck for the six months ended June 30, 2023, with **$5.6 million** in deferred revenue remaining[95](index=95&type=chunk) - In July 2023, subsequent to the quarter's end, the company closed an underwritten offering of common stock and pre-funded warrants, resulting in estimated net proceeds of **$56.5 million**[97](index=97&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's focus on developing its TRACTr and TRACIr platforms, with two clinical candidates in Phase 1 trials, and its strong liquidity position bolstered by a recent $56.5 million capital raise - The company is a clinical-stage biopharmaceutical firm developing tumor-activated immunotherapies, with lead candidates JANX007 and JANX008 currently in Phase 1 clinical trials[99](index=99&type=chunk) - As of June 30, 2023, the company had cash, cash equivalents, restricted cash, and short-term investments of **$304.1 million**, supplemented by a **$56.5 million** net capital raise in July 2023[129](index=129&type=chunk)[133](index=133&type=chunk) - Management believes that existing cash, cash equivalents, and short-term investments are sufficient to meet anticipated cash requirements for at least the next 12 months from the report's filing date[104](index=104&type=chunk)[139](index=139&type=chunk) [Results of Operations](index=27&type=section&id=Results%20of%20Operations) For the first six months of 2023, collaboration revenue decreased by $0.9 million, while research and development expenses increased by $6.5 million and general and administrative expenses rose by $2.8 million, partially offset by a $5.6 million increase in other income | Financial Performance (in thousands) | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | Change | | :--- | :--- | :--- | :--- | | Collaboration revenue | $3,105 | $3,954 | ($849) | | Research and development | $30,789 | $24,270 | $6,519 | | General and administrative | $13,345 | $10,487 | $2,858 | | Loss from operations | ($41,029) | ($30,803) | ($10,226) | | Other income | $6,062 | $505 | $5,557 | | **Net loss** | **($34,967)** | **($30,298)** | **($4,669)** | - The **$6.5 million** increase in R&D expenses for the six months ended June 30, 2023, was primarily due to a **$4.8 million** increase in indirect costs and a **$1.8 million** net increase in direct program costs[125](index=125&type=chunk) [Liquidity and Capital Resources](index=29&type=section&id=Liquidity%20and%20Capital%20Resources) The company's principal liquidity sources are its $304.1 million in cash and investments as of June 30, 2023, further strengthened by a $56.5 million net capital raise in July 2023, with net cash used in operations at $29.0 million - The company maintains an ATM Equity Offering Sales Agreement with BofA Securities to sell up to **$150.0 million** of common stock, with the full amount remaining available as of June 30, 2023[132](index=132&type=chunk) - In July 2023, the company raised estimated net proceeds of **$56.5 million** from an underwritten offering of common stock and pre-funded warrants[133](index=133&type=chunk) | Cash Flow Summary (in thousands) | Six Months Ended June 30, 2023 | | :--- | :--- | | Net cash used in operating activities | ($28,965) | | Net cash provided by investing activities | $9,134 | | Net cash provided by financing activities | $2,108 | [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=31&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company has indicated that this item is not applicable as it qualifies as a smaller reporting company - Disclosure is not applicable as the company is a smaller reporting company[146](index=146&type=chunk) [Item 4. Controls and Procedures](index=31&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and Acting CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of June 30, 2023, with no material changes in internal control over financial reporting during the quarter - The company's management concluded that disclosure controls and procedures were effective as of the end of the period covered by the report[147](index=147&type=chunk) - There were no changes in internal control over financial reporting during the most recent quarter that have materially affected, or are reasonably likely to materially affect, internal controls[149](index=149&type=chunk) [PART II. OTHER INFORMATION](index=33&type=section&id=PART%20II.%20OTHER%20INFORMATION) This section covers legal proceedings, risk factors, equity sales, other information, and exhibits [Item 1. Legal Proceedings](index=33&type=section&id=Item%201.%20Legal%20Proceedings) The company reports that it is not currently a party to any material legal proceedings - As of the filing date, the company is not involved in any material legal proceedings[152](index=152&type=chunk) [Item 1A. Risk Factors](index=33&type=section&id=Item%201A.%20Risk%20Factors) The company outlines significant risks including its limited operating history, history of net losses, need for substantial additional capital, uncertain development process, reliance on third parties, and intellectual property protection challenges - The company has a limited operating history, has incurred net losses since inception, and anticipates significant future losses, with no guarantee of achieving or sustaining profitability[155](index=155&type=chunk)[157](index=157&type=chunk) - The company is in the early stages of development, with most product candidates in preclinical or discovery stages, facing a lengthy, expensive, and uncertain development process with no guarantee of regulatory approval[155](index=155&type=chunk)[167](index=167&type=chunk) - Key operational risks include reliance on third parties for conducting clinical trials and manufacturing, and the ability to obtain and maintain sufficient intellectual property protection for its platform technologies and product candidates[155](index=155&type=chunk)[208](index=208&type=chunk)[305](index=305&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=81&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section details the use of proceeds from the company's June 2021 Initial Public Offering (IPO), which generated gross proceeds of $222.9 million, none of which have been used as of June 30, 2023 - The company's June 2021 IPO generated gross proceeds of **$222.9 million** from the sale of **13,110,000 shares** at **$17.00 per share**[412](index=412&type=chunk) - As of June 30, 2023, none of the IPO proceeds have been used, with funds invested in high-quality marketable securities until needed for operations[413](index=413&type=chunk) [Item 5. Other Information](index=81&type=section&id=Item%205.%20Other%20Information) The company states that no director or officer adopted or terminated a Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement during the three months ended June 30, 2023 - No director or officer adopted or terminated any Rule 10b5-1 or non-Rule 10b5-1 trading arrangement during the second quarter of 2023[414](index=414&type=chunk) [Item 6. Exhibits](index=82&type=section&id=Item%206.%20Exhibits) This section provides a list of all exhibits filed with the Quarterly Report on Form 10-Q, including the company's amended and restated certificate of incorporation, bylaws, and various officer certifications - Lists the exhibits filed with the Form 10-Q, including corporate governance documents and required SEC certifications[415](index=415&type=chunk)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40475 Janux Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 82-2289112 | ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40475 Janux Therapeutics, Inc. (Exact name of Registrant as specified in its Charter) | Delaware | 82-2289112 | | - ...

[PART I. FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) The unaudited condensed financial statements for the period ended September 30, 2022, reflect a decrease in total assets to $375.8 million, a significant increase in total liabilities to $44.2 million due to new operating lease liabilities, and a net loss of $47.0 million for the nine months, leading to an accumulated deficit of $94.4 million and $31.0 million in net cash used in operating activities [Condensed Balance Sheets](index=3&type=section&id=Condensed%20Balance%20Sheets) As of September 30, 2022, Janux Therapeutics had total assets of $375.8 million, a slight decrease from $379.8 million at the end of 2021, with total liabilities increasing to $44.2 million from $13.5 million, primarily due to new operating lease liabilities, resulting in stockholders' equity decreasing to $331.5 million Condensed Balance Sheet Highlights (in thousands) | Account | Sep 30, 2022 (unaudited) | Dec 31, 2021 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $64,752 | $35,582 | | Short-term investments | $274,008 | $339,383 | | Total current assets | $344,330 | $377,019 | | Total assets | $375,756 | $379,824 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $16,335 | $12,797 | | Operating lease liabilities, net | $24,092 | $0 | | Total liabilities | $44,243 | $13,497 | | Accumulated deficit | $(94,405) | $(47,411) | | Total stockholders' equity | $331,513 | $366,327 | | Total liabilities and stockholders' equity | $375,756 | $379,824 | [Unaudited Condensed Statements of Operations and Comprehensive Loss](index=4&type=section&id=Unaudited%20Condensed%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) For the third quarter of 2022, the company reported collaboration revenue of $1.8 million and a net loss of $16.7 million, increasing to a net loss of $47.0 million for the nine months ended September 30, 2022, primarily due to higher research and development and general and administrative expenses Statement of Operations Summary (in thousands, except per share data) | Metric | Q3 2022 | Q3 2021 | Nine Months 2022 | Nine Months 2021 | | :--- | :--- | :--- | :--- | :--- | | Collaboration revenue | $1,813 | $1,159 | $5,767 | $2,021 | | Research and development | $13,737 | $8,406 | $38,007 | $15,068 | | General and administrative | $6,098 | $3,656 | $16,585 | $6,392 | | Loss from operations | $(18,022) | $(10,903) | $(48,825) | $(19,439) | | Net loss | $(16,696) | $(10,766) | $(46,994) | $(19,256) | | Net loss per share | $(0.40) | $(0.26) | $(1.13) | $(1.10) | [Unaudited Condensed Statements of Cash Flows](index=7&type=section&id=Unaudited%20Condensed%20Statements%20of%20Cash%20Flows) For the nine months ended September 30, 2022, net cash used in operating activities significantly increased to $31.0 million, while net cash provided by investing activities was $59.9 million due to maturities of short-term investments, contrasting with minimal cash from financing activities compared to the prior year's IPO proceeds Cash Flow Summary for the Nine Months Ended September 30 (in thousands) | Activity | 2022 | 2021 | | :--- | :--- | :--- | | Net cash used in operating activities | $(31,009) | $(6,495) | | Net cash provided by (used in) investing activities | $59,870 | $(348,289) | | Net cash provided by financing activities | $309 | $386,360 | | **Net increase in cash, cash equivalents and restricted cash** | **$29,170** | **$31,576** | [Notes to Unaudited Condensed Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Condensed%20Financial%20Statements) The notes detail the company's accounting policies, its status as a clinical-stage biopharmaceutical company with an accumulated deficit of $94.4 million, and management's belief in sufficient capital for the next 12 months, alongside specifics on the Merck collaboration and other commitments - The company is a **clinical-stage biopharmaceutical company** developing immunotherapies using its proprietary **TRACTr** and **TRACIr** platforms[18](index=18&type=chunk) - Management believes the company has **sufficient capital** to fund operations for **at least 12 months** from the report's issuance date, despite a history of net losses and an accumulated deficit of **$94.4 million**[19](index=19&type=chunk) - Under the Merck Agreement, Janux recognized **$1.8 million** and **$5.8 million** in revenue for the three and nine months ended September 30, 2022, respectively, with aggregate deferred revenue related to the agreement totaling **$9.7 million** as of this date[103](index=103&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=22&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's clinical-stage biopharmaceutical focus, progress on lead programs like JANX007 and JANX008, and the increased net loss of $47.0 million for the nine months ended September 30, 2022, driven by higher R&D and G&A expenses, while affirming sufficient capital for at least the next 12 months - Janux is a **clinical-stage company** with lead programs targeting **PSMA (JANX007)**, **EGFR (JANX008)**, and **TROP2**, with the first patient dosed with JANX007 in a **Phase 1 trial** in **October 2022**, and an interim update expected in the **second half of 2023**[106](index=106&type=chunk) Comparison of Operations for the Nine Months Ended September 30 (in thousands) | Metric | 2022 | 2021 | Change | | :--- | :--- | :--- | :--- | | Collaboration revenue | $5,767 | $2,021 | $3,746 | | Research and development | $38,007 | $15,068 | $22,939 | | General and administrative | $16,585 | $6,392 | $10,193 | | Net loss | $(46,994) | $(19,256) | $(27,738) | - The **$22.9 million** increase in R&D expenses for the nine months ended Sep 30, 2022, was primarily driven by a **$12.3 million** increase in preclinical program costs and an **$11.2 million** increase in indirect costs, including personnel, stock-based compensation, and facilities[133](index=133&type=chunk) - As of September 30, 2022, the company had **$339.6 million** in cash, cash equivalents, restricted cash, and short-term investments, which is believed to be sufficient to fund operations for **at least the next 12 months**[137](index=137&type=chunk)[142](index=142&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=29&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This item is not applicable as the company qualifies as a smaller reporting company - Disclosure about market risk is **not applicable** as the company is a **smaller reporting company**[150](index=150&type=chunk) [Item 4. Controls and Procedures](index=29&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and Acting CFO, concluded that the company's disclosure controls and procedures were effective as of September 30, 2022, with no material changes in internal control over financial reporting during the most recent quarter - Management concluded that as of the end of the period covered by the report, the company's disclosure controls and procedures were **effective**[151](index=151&type=chunk) - **No changes** occurred in the company's internal control over financial reporting during the most recent quarter that have **materially affected**, or are reasonably likely to materially affect, internal controls[152](index=152&type=chunk) [PART II. OTHER INFORMATION](index=30&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=30&type=section&id=Item%201.%20Legal%20Proceedings) The company reports that it is not currently a party to any material legal proceedings - As of the filing date, the company is **not a party** to any **material legal proceedings**[154](index=154&type=chunk) [Item 1A. Risk Factors](index=30&type=section&id=Item%201A.%20Risk%20Factors) This section outlines significant risks to the company's business, including a limited operating history with substantial net losses, the ongoing need for additional capital, the early stage of its product candidates, reliance on third parties for trials and manufacturing, and challenges in intellectual property protection and regulatory approval - The company has a **limited operating history**, has incurred **net losses since inception**, and anticipates continued significant losses, potentially meaning it may **never achieve or sustain profitability**[157](index=157&type=chunk)[159](index=159&type=chunk) - All product candidates except JANX007 are in **preclinical or discovery stages**, and the company has **no history of conducting human clinical trials**, making development **lengthy, expensive, and uncertain**[157](index=157&type=chunk)[169](index=169&type=chunk) - The company **relies on third parties** for conducting **clinical trials and manufacturing**, which poses risks if these parties **do not perform their duties satisfactorily**[157](index=157&type=chunk)[212](index=212&type=chunk) - **Failure to obtain and maintain sufficient intellectual property protection** for its platform technologies and product candidates could allow competitors to develop similar products, **adversely affecting commercialization**[157](index=157&type=chunk)[306](index=306&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=78&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company details its June 2021 Initial Public Offering (IPO), where it sold 13,110,000 shares at $17.00 per share, generating net proceeds of approximately $204.2 million, none of which have been used as of September 30, 2022 - In its **June 2021 IPO**, the company sold **13,110,000 shares** at **$17.00 per share**, raising gross proceeds of **$222.9 million** and net proceeds of approximately **$204.2 million**[417](index=417&type=chunk) - As of September 30, 2022, **none of the IPO proceeds have been used** and are invested in U.S. Treasury securities, corporate debt, and commercial paper in line with the company's investment policy[418](index=418&type=chunk) [Item 5. Other Information](index=78&type=section&id=Item%205.%20Other%20Information) On November 8, 2022, Dr. Shahram Salek-Ardakani resigned as Chief Scientific Officer and entered into a 12-month consulting agreement with the company for a monthly fee of $33,333.33 - Shahram Salek-Ardakani, Ph.D. **resigned as Chief Scientific Officer** on **November 8, 2022**, and entered into a **12-month consulting agreement** with the company[419](index=419&type=chunk) [Item 6. Exhibits](index=79&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Quarterly Report on Form 10-Q, including corporate governance documents, material agreements, and officer certifications - Lists **all exhibits filed** with the Form 10-Q, including **corporate governance documents**, **material agreements**, and **officer certifications** required by the Sarbanes-Oxley Act[422](index=422&type=chunk)

Developing Tumor Activated T Cell Therapeutics September 2022 2 Forward-looking statements and disclaimers This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements regarding Janux Therapeutics, Inc. (the "Company"). These forward-looking statement include, but are not limited to, those regarding the Com ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40475 Janux Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2289112 ( Stat ...

Developing Tumor Activated T Cell Therapeutics May 2022 2 Forward-looking statements and disclaimers This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements regarding Janux Therapeutics, Inc. (the "Company"). These forward-looking statement include, but are not limited to, those regarding the Company's ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40475 Janux Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 82-2289112 ( Sta ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40475 Janux Therapeutics, Inc. (Exact name of registrant as specified in its Charter) Delaware 82-2289112 (State or ...

Developing Tumor Activated T Cell Therapeutics March 2022 2 Forward-looking statements and disclaimers Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of any of its contents is prohibited. This presentation includes certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements regarding Ja ...